



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



**Date: 13 February 2026**

<b>To</b> <b>BSE Limited</b> Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400001	<b>To</b> <b>National Stock Exchange of India Limited</b> Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai – 400051
<b>Security Code: 540596</b>	<b>Symbol: ERIS</b>

**SUBJECT: OUTCOME OF THE BOARD MEETING HELD TODAY, i.e., FRIDAY, FEBRUARY 13, 2026**

Dear Sir/Madam,

Pursuant to Regulation 30 read with Regulation 51 (Part A and Part B of Schedule III) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (“**SEBI Listing Regulations**”) we hereby inform you that the Board of Directors of the Company, in their meeting held today, i.e., Friday, February 13, 2026, inter alia, duly approved and took on record the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2025.

In this regard, the following documents are enclosed:

- A copy of the said financial results along with the limited review report pursuant to Regulation 33 and Regulation 52 of the SEBI Listing Regulations. The limited review reports are submitted with unmodified opinion(s) (free from any qualifications).
- Details as per Regulation 52(4) of SEBI Listing Regulations.

The meeting of the Board of Directors commenced at 11:30 A.M. and concluded at 01:10 P.M.

This is for your information and record.

Thanking You,

**For Eris Lifesciences Limited**

---

**Milind Talegaonkar**  
**Company Secretary & Compliance Officer**  
**Membership No: A26493**

**Registered & Corporate Office:**

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054  
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867

# Walker Chandiook & Co LLP

---

## Walker Chandiook & Co LLP

Block No. D/15th Floor,  
Cabin No. A8 to A10  
"West Gate" Near YMCA Club, S.G  
Highway, Sarkhej Road,  
Ahmedabad-380015  
Gujarat, India

### **Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

#### **To the Board of Directors of Eris Lifesciences Limited**

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Eris Lifesciences Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), and joint venture (refer Annexure 1 for the list of subsidiaries and joint venture included in the Statement) for the quarter ended 31 December 2025 and the consolidated year to date results for the period 1 April 2025 to 31 December 2025, being submitted by the Holding Company pursuant to the requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



---

Chartered Accountants

Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Hyderabad, Indore, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

---

Walker Chandiook & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

## Walker ChandioK & Co LLP

### Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd)


We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review reports of the other auditors referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We did not review the financial results of 6 subsidiaries included in the Statement, whose financial information reflects total revenues of ₹ 180.49 Crores and ₹ 441.98 Crores, total net profit after tax of ₹ 25.75 Crores and ₹ 102.93 Crores, total comprehensive income of ₹ 25.53 Crores and ₹ 102.61 Crores, for the quarter and nine-months period ended on 31 December 2025, respectively, as considered in the Statement. The Statement also includes the Group's share of net profit after tax of ₹ 0.12 Crores and ₹ 1.29 Crores and total comprehensive income of ₹ 0.12 Crores and ₹ 1.29 Crores for the quarter and nine-months period ended on 31 December 2025, respectively, as considered in the Statement, in respect of joint venture, whose interim financial results have not been reviewed by us. These financial results have been reviewed by other auditors whose review reports have been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and joint venture is based solely on the review reports of such other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter with respect to our reliance on the work done by and the reports of the other auditors.

6. The review of unaudited consolidated quarterly and year-to-date financial results for the period ended 31 December 2024 and audit of consolidated financial results for the year ended 31 March 2025 included in the Statement was carried out and reported by Deloitte Haskins & Sells LLP, who have expressed unmodified conclusion vide their review report dated 4 February 2025 and unmodified opinion vide their audit report dated 19 May 2025, respectively, whose reports have been furnished to us and which have been relied upon by us for the purpose of our review of the Statement. Our conclusion is not modified in respect of this matter.

**For Walker ChandioK & Co LLP**  
Chartered Accountants  
Firm Registration No: 001076N/N500013

  
**Ashish Gupta**  
Partner  
Membership No: 504662  
UDIN: 26504662BWGQMJ1959

**Place:** Ahmedabad  
**Date:** 13 February 2026



# Walker ChandioK & Co LLP

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd)

---

## Annexure 1

### List of entities included in the Statement

#### Holding Company

Sr. No.	Name of entity
1	Eris Lifesciences Limited

#### Subsidiaries

Sr. No.	Name of entities
1	Eris Therapeutics Limited
2	Aprica Healthcare Limited (Step-down subsidiary)
3	Eris Oaknet Healthcare Private Limited (Step-down subsidiary)
4	Eris Healthcare Private Limited
5	Eris M. J. Biopharm Private Limited
6	Eris Pharmaceuticals Limited (Formerly known as Eris Pharmaceuticals Private Limited)
7	Eris Bionxt Private Limited (Formerly known as Chemman Labs Private Limited)
8	Swiss Parenterals Limited

#### Joint venture

Sr. No.	Name of entity
1	Levim Lifetech Private Limited





EY Entrepreneur  
of the year-2013



FROST & SULLIVAN  
Best Practices-2013



Business today/YES bank  
Excellence Awards-2013



Eris Lifesciences Limited

Statement of Unaudited Consolidated Financial results for the Quarter and Nine Months ended December 31, 2025

Sr. No.	Particulars	[Rs in Crore except per share data]					
		For Quarter ended			For Nine Months ended		For year ended
		December 31, 2025 (Unaudited)	September 30, 2025 (Unaudited)	December 31, 2024 (Unaudited) (Refer note 7)	December 31, 2025 (Unaudited)	December 31, 2024 (Unaudited) (Refer note 7)	March 31, 2025 (Audited)
1	<b>Income</b>						
	<b>Revenue from operations</b>						
	Sale of products	800.89	790.15	722.12	2,362.60	2,176.66	2,879.26
	Other operating income	6.56	2.26	5.33	10.26	11.68	14.38
	<b>Total Revenue from operations</b>	<b>807.45</b>	<b>792.41</b>	<b>727.45</b>	<b>2,372.86</b>	<b>2,188.34</b>	<b>2,893.64</b>
	Other income	0.02	2.81	4.22	5.52	10.41	18.36
	<b>Total income</b>	<b>807.47</b>	<b>795.22</b>	<b>731.67</b>	<b>2,378.38</b>	<b>2,198.75</b>	<b>2,912.00</b>
2	<b>Expenses</b>						
	Cost of materials consumed	105.85	82.58	69.43	258.53	208.06	276.34
	Purchase of stock-in-trade	117.24	146.09	133.22	367.59	377.14	473.12
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.21	(26.26)	(25.77)	(15.77)	(41.46)	(35.47)
	Employee benefits expense	138.08	137.45	125.39	419.96	383.64	505.09
	Finance costs	48.82	49.55	57.17	147.05	177.01	231.29
	Depreciation and amortisation expense	70.34	69.08	81.00	209.93	237.12	315.46
	Other expenses	164.46	164.34	174.87	496.02	496.15	657.36
	<b>Total expenses</b>	<b>645.00</b>	<b>622.83</b>	<b>615.31</b>	<b>1,883.31</b>	<b>1,837.66</b>	<b>2,423.19</b>
3	<b>Profit before share of profit from investment in joint venture and tax for the period / year (1-2)</b>	<b>162.47</b>	<b>172.39</b>	<b>116.36</b>	<b>495.07</b>	<b>361.09</b>	<b>488.81</b>
4	Share of (profit) from investment in joint venture, net of tax	(0.12)	(0.28)	-	(1.29)	-	(0.06)
5	<b>Profit before tax and exceptional item for the period / year (3-4)</b>	<b>162.59</b>	<b>172.67</b>	<b>116.36</b>	<b>496.36</b>	<b>361.09</b>	<b>488.87</b>
6	Exceptional items (Refer note 5)	17.24	-	-	17.24	-	-
7	<b>Profit before tax for the period / year (5-6)</b>	<b>145.35</b>	<b>172.67</b>	<b>116.36</b>	<b>479.12</b>	<b>361.09</b>	<b>488.87</b>
8	<b>Tax Expense</b>						
	Current tax	17.43	71.18	24.86	144.92	80.45	111.84
	Deferred tax	19.09	(32.98)	4.44	(34.20)	7.62	2.36
	<b>Total tax expense</b>	<b>36.52</b>	<b>38.20</b>	<b>29.30</b>	<b>110.72</b>	<b>88.07</b>	<b>114.20</b>
9	<b>Net profit for the period / year (7-8)</b>	<b>108.83</b>	<b>134.47</b>	<b>87.06</b>	<b>368.40</b>	<b>273.02</b>	<b>374.67</b>
	Attributable to :						
	- Owners of the Company	99.72	120.19	83.76	337.90	258.71	351.84
	- Non controlling interest	9.11	14.28	3.30	30.50	14.31	22.83
10	<b>Other comprehensive loss</b>						
	Items that will not be reclassified to profit or loss						
	Re-measurement gains / (losses) on defined benefit plans	(0.84)	(0.84)	(0.57)	(2.52)	(2.01)	(3.63)
	Income tax effect	0.27	0.27	0.18	0.81	0.67	0.34
	Items that will be reclassified to profit or loss						
	Net movement on effective portion of cash flow hedges	(0.21)	-	-	(0.21)	-	-
	Income tax effect	0.04	-	-	0.04	-	-
	<b>Other comprehensive loss for the period / year, net of tax</b>	<b>(0.74)</b>	<b>(0.57)</b>	<b>(0.39)</b>	<b>(1.88)</b>	<b>(1.34)</b>	<b>(3.29)</b>
	Attributable to :						
	- Owners of the Company	(0.70)	(0.56)	(0.38)	(1.82)	(1.33)	(3.18)
	- Non controlling interest	(0.04)	(0.01)	(0.01)	(0.06)	(0.01)	(0.11)
11	<b>Total comprehensive income</b>						
	Attributable to :						
	- Owners of the Company	99.02	119.63	83.38	336.08	257.38	348.66
	- Non controlling interest	9.07	14.27	3.29	30.44	14.30	22.72
	<b>Total comprehensive income for the period / year (9+10)</b>	<b>108.09</b>	<b>133.90</b>	<b>86.67</b>	<b>366.52</b>	<b>271.68</b>	<b>371.38</b>
12	Paid Up Equity Share Capital (Face Value of Rs 1 each)	13.62	13.62	13.61	13.62	13.61	13.62
13	Other Equity						2,840.74
14	Earnings Per Share (of Rs 1 each) (not annualised) :						
	Basic	7.32	8.82	6.15	24.81	18.99	25.85
	Diluted	7.31	8.81	6.14	24.77	18.96	25.81




Registered & Corporate Office:

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054  
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867

Additional information pursuant to Regulation 52(4) of Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015 as amended for the quarter and nine months ended December 31, 2025

Particulars	Quarter ended			Nine months ended		Year ended
	December 31, 2025 (Unaudited)	September 30, 2025 (Unaudited)	December 31, 2024 (Unaudited) (Refer note 7)	December 31, 2025 (Unaudited)	December 31, 2024 (Unaudited) (Refer note 7)	March 31, 2025 (Audited)
<b>Debt – Equity Ratio (in times)</b> (Total Debt(including lease liabilities)/Total Equity)	0.67	0.68	0.79	0.67	0.79	0.76
<b>Debt Service Coverage Ratio (in times)</b> (Profit after tax-Other income+ Depreciation and amortisation expense+Finance Costs+Committed Principal repayments made during the period for long term loans/Finance Costs +Committed Principal repayments made during the period for long term loans)	2.48	2.65	2.27	2.58	2.20	2.24
<b>Interest service coverage ratio (in times)</b> (Earnings before share of profit from joint venture, exceptional items, Interest and Tax/Finance Costs)	4.33	4.48	3.04	4.37	3.04	3.11
<b>Outstanding redeemable preference shares (quantity and value)</b>	NA	NA	NA	NA	NA	NA
<b>Capital redemption reserve/debenture redemption reserve (Rs in crore)</b>	0.17	0.17	0.17	0.17	0.17	0.17
<b>Net worth (Rs in crore)</b>	3,610.87	3,503.48	3,267.41	3,610.87	3,267.41	3,271.76
<b>Net profit after tax (Rs in crore)</b>	108.83	134.47	87.06	368.40	273.02	374.67
<b>Earnings per share</b>						
Basic	7.32	8.82	6.15	24.81	18.99	25.85
Diluted	7.31	8.81	6.14	24.77	18.96	25.81
<b>Current Ratio (in times)</b> (Current Assets/Current Liabilities)	0.69	0.91	1.03	0.69	1.03	0.89
<b>Long term debt to working capital (in times)</b> (Long-term borrowing+Lease liabilities including its current maturity/Current Assets-Current liabilities (excluding current maturity))	7.67	11.36	6.71	7.67	6.71	14.74
<b>Bad debts to account receivable ratio (in times)</b> (Bad debts/Trade receivables)	Nil	Nil	Nil	Nil	Nil	Nil
<b>Current liability ratio (in times)</b> (Current liabilities/Total liabilities)	0.60	0.42	0.34	0.60	0.34	0.37
<b>Total debts to total assets (in times)</b> (Total Debt (including lease liabilities)/Total Assets)	0.33	0.33	0.36	0.33	0.36	0.35
<b>Debtors' turnover* (in times)</b> (Sales/Trade receivables)	4.27	4.63	5.21	4.27	5.21	6.28
<b>Inventory Turnover* (in times)</b> (Cost of goods sold/Average Inventory)	2.24	2.21	2.90	2.24	2.90	2.73
<b>Operating margin percent</b> (Earnings before share of profit from joint venture, exceptional items, Interest and Tax/Revenue from Operations)	26.17%	28.01%	23.85%	27.06%	24.59%	24.89%
<b>Net profit margin percent</b> (Profit after tax/Revenue from Operations)	13.48%	16.97%	11.97%	15.53%	12.48%	12.95%

\*Quarterly ratios based on trailing twelve months values.



Notes to Unaudited Consolidated Financial results

- 1 The above statement of Unaudited Consolidated Financial results ("the Statement") have been recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 13, 2026.
- 2 The Unaudited Consolidated Financial results of the Holding Company have been prepared in accordance with recognition and measurement principles laid down in the Indian Accounting Standards ('Ind AS') 34, Interim Financial Reporting (Ind AS 34) as prescribed under Section 133 of the Companies Act, 2013 ('the Act') and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 (as amended).
- 3 The Holding Company has issued and allotted 54,322 ordinary shares of Rs 1 each under the Company's Employee Stock Option Scheme 2021 during the nine months period ended December 31, 2025. Consequently, the issued and paid-up Share Capital of the Company as on December 31, 2025 stands increased to Rs 13.62 crore.
- 4 The Holding Company is primarily engaged in one business segment namely - "Pharmaceuticals" - as determined by the chief operating decision maker in accordance with Ind AS 108 - "Operating Segment".
- 5 Effective November 21, 2025, The Government of India has consolidated multiple existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the 'New Labour Codes'. The Holding Company has assessed the financial implications of these changes which has resulted in increase in gratuity liability and leave liability arising out of past service cost by Rs 17.24 Crores primarily arising due to change in definition of "wages" for employees and contract labours. The Holding Company has presented such incremental impact under "Exceptional Item" in the consolidated financial results for the quarter and nine months ended December 31, 2025.
- 6 Subsequent to the end of the quarter, on January 16, 2026, the Company has completed the allotment of 23,06,372 fully paid up equity shares of Rs 1 each at an issue price of Rs. 1835.35 per equity share on preferential basis through private placement to the non-controlling interest holder of Swiss Parenterals Limited ("Swiss", "Subsidiary Company") for consideration other than cash in lieu of acquisition of 16,74,493 fully paid up equity shares of Rs. 10 each of Swiss representing 30% of the total share capital of the Subsidiary Company. As a result of the above acquisition, Swiss became a wholly owned subsidiary of the Company w.e.f. January 16, 2026.
- 7 During the year ended March 31, 2024, the Holding Company had acquired 51% stake in Swiss Parenterals Limited for a consideration (excluding acquisition expense) of Rs 637.50 crore. The Holding Company has completed the final determination of fair values of identified assets and liabilities for the purpose of Purchase Price Allocation for the aforesaid acquisitions in the previous year ended March 31, 2025. Consequent to above the Holding Company has restated the reported amounts of the previous periods as required by the applicable accounting standards.

The summarized position of the reported and restated amounts is as below:

(Rs in crore)

Particulars	For the Quarter ended December 31, 2024		For the nine months ended December 31, 2024	
	Reported	Restated	Reported	Restated
Profit before tax	116.16	116.36	360.59	361.09
Profit after tax	86.93	87.06	272.70	273.02
Total Other Comprehensive Income	86.54	86.67	271.36	271.68

- 8 During the previous year ended March 31, 2025, the Holding Company has acquired 1,43,13,418 equity shares representing 100% of the equity share capital of Eris Bionxt Private Limited (formerly known as Chemman Labs Private Limited), from its erstwhile shareholders for a consideration of Rs. 27 Crores. The transaction achieved closure in October 2024, on completion of all relevant conditions precedent to the transaction. The Holding Company has completed the final determination of fair values of identified assets and liabilities for the purpose of Purchase Price Allocation for the aforesaid acquisitions during the period, consequently there is no material changes in the provisional fair valuation report which was earlier accounted as part of Business Combination.
- 9 During the previous year ended March 31, 2025, the Holding Company has sold its equity investment in Eris Oaknet Healthcare Private Limited (EOHPL) and Aprica Healthcare Limited (AHL) to Eris Therapeutics Limited (ETL). As a result, EOHPL and AHL are now a wholly owned subsidiary of ETL.

During the nine months period ended December 31, 2025, taking into account the revised shareholding structure and other relevant factors arising from the above-mentioned transfer of stake, the ETL proposed the scheme whereby the "Domestic Business" of EOHPL shall get vested into ETL ("Resulting Company/Amalgamated Company") and AHL ("Amalgamating Company") would be amalgamated with ETL.

Accordingly, the respective Boards of Directors of ETL, AHL, and EOHPL have approved the Composite Scheme of Arrangement under Sections 230 to 232, read with Section 66 and other applicable provisions of the Companies Act, 2013. The scheme is subject to necessary statutory and regulatory approvals, as required under applicable laws.



For Eris Lifesciences Limited,

Amit Bakshi  
Chairman and Managing Director  
DIN : 01250925

Place: Ahmedabad  
Date: February 13, 2026

# Walker Chandiook & Co LLP

---

**Walker Chandiook & Co LLP**

Block No. D/15th Floor,  
Cabin No. A8 to A10  
"West Gate" Near YMCA Club,  
S.G Highway, Sarkhej Road,  
Ahmedabad-380015  
Gujarat, India

**Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

**To the Board of Directors of Eris Lifesciences Limited**

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Eris Lifesciences Limited ('the Company') for the quarter ended 31 December 2025 and the year to date results for the period 1 April 2025 to 31 December 2025, being submitted by the Company pursuant to the requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information



---

Chartered Accountants

Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Hyderabad, Indore, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

---

Walker Chandiook & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

## Walker Chandiook & Co LLP

### Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd)


---

required to be disclosed in accordance with the requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. The review of standalone unaudited quarterly and year-to-date financial results for the period ended 31 December 2024 and audit of standalone financial results for the year ended 31 March 2025 included in the Statement was carried out and reported by Deloitte Haskins & Sells LLP, who has expressed unmodified conclusion vide their review report dated 4 February 2025 and unmodified opinion vide their audit report dated 19 May 2025, respectively, whose reports have been furnished to us and which have been relied upon by us for the purpose of our review of the Statement. Our conclusion is not modified in respect of this matter.

#### For Walker Chandiook & Co LLP

Chartered Accountants  
Firm Registration No: 001076N/N500013

  
**Ashish Gupta**  
Partner  
Membership No. 504662  
UDIN: 26504662QBJSPW9524



**Place:** Ahmedabad  
**Date:** 13 February 2026



Statement of Unaudited Standalone Financial Results for the Quarter and Nine Months Ended December 31, 2025

		[Rs. in Crore except per share data]					
Sr. No.	Particulars	For Quarter ended			For Nine Months ended		For Year ended
		December 31, 2025 (Unaudited)	September 30, 2025 (Unaudited)	December 31, 2024 (Unaudited)	December 31, 2025 (Unaudited)	December 31, 2024 (Unaudited)	March 31, 2025 (Audited)
1	<b>Income</b>						
	<b>Revenue from Operations</b>						
	Sale of products	306.78	637.58	390.00	1,512.25	1,267.92	1,663.63
	Other operating income	8.51	12.92	9.73	32.18	25.06	34.12
	<b>Total Revenue from Operations</b>	<b>315.29</b>	<b>650.50</b>	<b>399.73</b>	<b>1,544.43</b>	<b>1,292.98</b>	<b>1,697.75</b>
	Other Income	25.07	23.59	7.79	71.34	18.76	35.51
	<b>Total Income</b>	<b>340.36</b>	<b>674.09</b>	<b>407.52</b>	<b>1,615.77</b>	<b>1,311.74</b>	<b>1,733.26</b>
2	<b>Expenses</b>						
	Cost of materials consumed	17.05	20.29	10.93	61.46	58.52	68.35
	Purchase of stock-in-trade	113.75	134.83	122.67	355.27	355.42	474.44
	Changes in inventories of finished goods, work-in- progress and stock-in-trade	(20.77)	42.27	(14.52)	72.21	(39.01)	(43.54)
	Employee benefits expense	82.75	85.42	87.04	261.95	280.51	361.92
	Finance costs	45.20	46.50	54.65	136.84	167.08	220.24
	Depreciation and amortisation expense	38.66	39.30	46.68	115.56	138.39	181.77
	Other expenses	45.16	70.81	94.04	202.99	271.96	350.03
	<b>Total expenses</b>	<b>321.80</b>	<b>439.42</b>	<b>401.49</b>	<b>1,206.28</b>	<b>1,232.87</b>	<b>1,613.21</b>
3	<b>Profit before exceptional items and tax for the period / year(1-2)</b>	<b>18.56</b>	<b>234.67</b>	<b>6.03</b>	<b>409.49</b>	<b>78.87</b>	<b>120.05</b>
4	Exceptional items (Refer note 4)	14.67	-	-	14.67	-	-
5	<b>Profit before tax for the period / year (3-4)</b>	<b>3.89</b>	<b>234.67</b>	<b>6.03</b>	<b>394.82</b>	<b>78.87</b>	<b>120.05</b>
6	<b>Tax expense</b>						
	Current tax	0.51	40.91	-	68.59	13.47	21.98
	Deferred tax	0.29	44.19	4.25	73.58	18.48	20.68
	<b>Total tax expense</b>	<b>0.80</b>	<b>85.10</b>	<b>4.25</b>	<b>142.17</b>	<b>31.95</b>	<b>42.66</b>
7	<b>Net profit for the period / year (5-6)</b>	<b>3.09</b>	<b>149.57</b>	<b>1.78</b>	<b>252.65</b>	<b>46.92</b>	<b>77.39</b>
8	<b>Other Comprehensive loss</b>						
	Items that will not be reclassified to profit or (loss)						
	Re-measurement gains / (losses) on defined benefit plans	(0.77)	(0.77)	(0.64)	(2.31)	(1.92)	(3.10)
	Income tax effect	0.27	0.27	0.22	0.81	0.67	0.26
	<b>Other Comprehensive loss for the period / year, net of tax</b>	<b>(0.50)</b>	<b>(0.50)</b>	<b>(0.42)</b>	<b>(1.50)</b>	<b>(1.25)</b>	<b>(2.84)</b>
9	<b>Total Comprehensive Income for the period / year (7+8)</b>	<b>2.59</b>	<b>149.07</b>	<b>1.36</b>	<b>251.15</b>	<b>45.67</b>	<b>74.55</b>
10	Paid Up Equity Share Capital (Face Value of Rs 1 each)	13.62	13.62	13.61	13.62	13.61	13.62
11	Other Equity						2,501.28
12	Earnings Per Share (of Rs 1 each) (not annualised) :						
	Basic	0.23	10.98	0.13	18.55	3.45	5.69
	Diluted	0.23	10.96	0.13	18.52	3.44	5.68



Registered & Corporate Office:

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054  
 Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867

Additional information pursuant to Regulation 52(4) of Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015 as amended for the quarter and nine months ended December 31, 2025

Particulars	Quarter ended			For Nine Months ended		Year ended March 31, 2025 (Audited)
	December 31, 2025 (Unaudited)	September 30, 2025 (Unaudited)	December 31, 2024 (Unaudited)	December 31, 2025 (Unaudited)	December 31, 2024 (Unaudited)	
<b>Debt – Equity Ratio (in times)</b> (Total Debt(including lease liabilities)/Total Equity)	0.77	0.79	0.97	0.77	0.97	0.89
<b>Debt Service Coverage Ratio (in times)</b> (Profit after tax-Other income+ Depreciation and amortisation expense+Finance Costs+Committed Principal repayments made during the period for long term loans/Finance Costs +Committed Principal repayments made during the period for long term loans)	1.16	2.61	1.37	1.97	1.47	1.48
<b>Interest service coverage ratio (in times)</b> (Earnings before exceptional items, Interest and Tax/Finance Costs)	1.41	6.05	1.11	3.99	1.47	1.55
<b>Outstanding redeemable preference shares (quantity and value)</b>	NA	NA	NA	NA	NA	NA
<b>Capital redemption reserve/debenture redemption reserve (Rs in crore)</b>	0.17	0.17	0.17	0.17	0.17	0.17
<b>Net worth (Rs in crore)</b>	2,775.38	2,770.57	2,581.40	2,775.38	2,581.40	2,514.90
<b>Net profit after tax (Rs in crore)</b>	3.09	149.57	1.78	252.65	46.92	77.39
<b>Earnings per share</b>						
Basic	0.23	10.98	0.13	18.55	3.45	5.69
Diluted	0.23	10.96	0.13	18.52	3.44	5.68
<b>Current Ratio (in times)</b> (Current Assets/Current Liabilities)	0.59	1.00	0.75	0.59	0.75	0.63
<b>Long term debt to working capital (in times)</b> (Long-term borrowing+Lease liabilities including its current maturity/Current Assets-Current liabilities (excluding current maturity))	13.32	7.52	(30.59)	13.32	(30.59)	(14.23)
<b>Bad debts to account receivable ratio (in times)</b> (Bad debts/ Trade receivables)	Nil	Nil	Nil	Nil	Nil	Nil
<b>Current liability ratio (in times)</b> (Current liabilities/Total liabilities)	0.67	0.41	0.40	0.67	0.40	0.37
<b>Total debts to total assets (in times)</b> (Total Debt (including lease liabilities)/Total Assets)	0.40	0.40	0.45	0.40	0.45	0.43
<b>Debtors' turnover* (in times)</b> (Sales/ Trade receivables)	3.74	2.97	6.71	3.74	6.71	7.04
<b>Inventory Turnover* (in times)</b> (Cost of goods sold/Average Inventory)	4.19	4.89	3.20	4.19	3.20	3.53
<b>Operating margin percent</b> (Earnings before exceptional items, Interest and Tax/Revenue from Operations)	20.22%	43.22%	15.18%	35.37%	19.02%	20.04%
<b>Net profit margin percent</b> (Profit after tax/Revenue from Operations)	0.98%	22.99%	0.45%	16.36%	3.63%	4.56%

\*Quarterly ratios based on trailing twelve months values.



## Notes to Unaudited Standalone Financial results

- 1 The above statement of Unaudited Standalone Financial results ("the Statement") have been recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 13, 2026.
- 2 The Unaudited Standalone Financial results of the Company have been prepared in accordance with recognition and measurement principles laid down in the Indian Accounting Standards ('Ind AS') 34, Interim Financial Reporting (Ind AS 34) as prescribed under Section 133 of the Companies Act, 2013 ('the Act') and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 (as amended).
- 3 The Company has issued and allotted 54,322 ordinary shares of Rs 1 each under the Company's Employee Stock Option Scheme 2021 during the nine months period ended December 31, 2025. Consequently, the issued and paid-up Share Capital of the Company as on December 31, 2025 stands increased to Rs 13.62 crore.
- 4 Effective November 21, 2025, The Government of India has consolidated multiple existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the 'New Labour Codes'. The Company has assessed the financial implications of these changes which has resulted in increase in gratuity liability and leave liability arising out of past service cost by Rs 14.67 Crores primarily arising due to change in definition of "wages" for employees and contract labours. The Company has presented such incremental impact under "Exceptional Item" in the standalone financial results for the quarter and nine months ended December 31, 2025.
- 5 Subsequent to the end of the quarter, on January 16, 2026, the Company has completed the allotment of 23,06,372 fully paid up equity shares of Rs 1 each at an issue price of Rs. 1835.35 per equity share on preferential basis through private placement to the non-controlling interest holder of Swiss Parenterals Limited ("Swiss", "Subsidiary Company") for consideration other than cash in lieu of acquisition of 16,74,493 fully paid up equity shares of Rs. 10 each of Swiss representing 30% of the total share capital of the Subsidiary Company. As a result of the above acquisition, Swiss became a wholly owned subsidiary of the Company w.e.f. January 16, 2026.
- 6 The Company is primarily engaged in one business segment namely - "Pharmaceuticals" - as determined by the chief operating decision maker in accordance with Ind AS 108 - "Operating Segment".



For Eris Lifesciences Limited,

Amit Bakshi  
Chairman and Managing Director  
DIN : 01250925

Place: Ahmedabad  
Date: February 13, 2026